К содержанию
Dr. Tara EinullaevaMedical oncologist

Cancer glossary

KRAS mutation: what it means in lung and colorectal cancer

What a KRAS mutation on your report means: why G12C matters, why colorectal cancer is tested for both KRAS and NRAS, and how the result changes treatment.

Written and medically reviewed by

Dr. Tara Einullaeva

Medical oncologist, 9 years in practice. Credentials · reviewed 17 October 2026

In short

KRAS is the gene for a protein that signals the cell to divide. Its mutations occur in lung, colorectal, pancreatic and other cancers; depending on the tumor and the variant, the result either opens up targeted treatment or rules out certain drugs.

How it appears in your report

  • ‘KRAS: G12C mutation detected (exon 2)’ — a change at codon 12 to cysteine; inhibitors exist for it.
  • ‘KRAS G12D’ or ‘KRAS G13D’ — other variants; G12C inhibitors do not work for them.
  • ‘KRAS, NRAS (exons 2, 3, 4): no mutations detected’ — RAS wild-type, typical wording in colorectal cancer.
  • ‘KRAS mutation detected, BRAF not tested’ — in colorectal cancer, RAS and BRAF are usually checked together.

What it means

Cancer What the result means
Non-small cell lung cancer KRAS mutations in 20–25% of patients; G12C in about 1 in 8. KRAS G12C inhibitors exist for G12C
Metastatic colorectal cancer with a mutation in KRAS or NRAS (exons 2, 3, 4), anti-EGFR antibodies are unlikely to help; with RAS wild-type they can be considered
Other cancers the meaning depends on the diagnosis and is discussed with your doctor

According to the AACR GENIE registry, G12C is found in 13.8% of patients with non-small cell lung cancer and only 3.2% of those with colorectal cancer.

Does it affect treatment

Yes. In lung cancer with G12C, KRAS inhibitors are usually considered after first-line systemic treatment. Tumors with KRAS mutations are often resistant to EGFR inhibitors. In colorectal cancer, the RAS result together with BRAF and MSI determines which drugs are added to chemotherapy. Your treating doctor makes the choice.

Questions to ask your doctor

  • Which KRAS variant exactly was found?
  • Were NRAS and BRAF checked (in colorectal cancer), or the full panel (in lung cancer)?
  • Are there drugs or clinical trials for my mutation?

More in the articles on colorectal cancer treatment and on mutations in lung cancer. I can help you understand the result in a consultation.

Sources

  1. Targeted Drug Therapy for Non-small Cell Lung Cancer — American Cancer Society, 2025
  2. Tests for Lung Cancer — American Cancer Society, 2024
  3. Extended RAS Mutation Testing in Metastatic Colorectal Cancer to Predict Response to Anti-EGFR Antibody Therapy — The ASCO Post (ASCO), 2015
  4. Prevalence of KRAS G12C Somatic Mutations by Cancer Type, Race, and Sex — The ASCO Post (NEJM, AACR GENIE), 2021

Watch me explain this on video

Short videos on my Instagram (in Russian)

FAQ

Related terms

This is reference information and not a substitute for medical advice. Your doctor interprets each value in the context of your whole situation.

Related articles

All blog articles